Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C lands $55mm for MicuRx

Executive Summary

Antibiotics developer MicuRx Pharmaceuticals Inc. raised $55mm in its Series C financing round led by GP Healthcare Capital, which adds a board member and was joined by other first-time backers GP TMT Capital, 3E Bioventures Capital, and Delian Capital. The company will use the proceeds to finish a Phase III study of its MRX1 for complicated skin and skin structure infections in China and file the NDA. Additional funds will support a US Phase III trial of the compound in acute bacterial skin and skin structure infections.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies